

SFDA SAFTEY COMMUNICATION

July 13th, 2014

Subject: Risk of hypersensitivity reactions of products containing ambroxol and bromhexine.

The Saudi Food and Drug Authority would like to inform the healthcare professionals and the public that after reviewing the safety profile for products containing ambroxol and bromhexine (secretolytic agents of acute and chronic bronchopulmonary diseases), it has been found that these drugs might be associated with rare but severe allergic reactions such as anaphylactic shock. The signs and symptoms of these reactions may include rash, itchy eyes, angioedema (swelling of the deeper layers of the skin) and breathing difficulties. Healthcare professionals should be aware of the risk of hypersensitivity reactions associated with these drugs and counsel patients about how to recognize the possible signs and symptoms. Patients should seek emergency medical attention immediately if they develop any signs and symptoms of a serious allergic reaction while taking these drugs.

The Saudi Food and Drug Authority (SFDA) continues to monitor the safety of pharmaceutical products in Saudi Arabia. For further information please contact us using the following information:

National Pharmacovigilance and Drug Safety Center (NPC) Saudi Food and Drug Authority-Drug sector 3292 Northern Ring Road Al Nafal District Riyadh 13312 – 6288 Kingdom of Saudi Arabia Toll free number: 8002490000

Tel: 0112038222 ext. 2317,2356, 5372, 2340, 5721

Fax: 0112057662

Email: NPC.Drug@sfda.gov.sa